期刊文献+

CCR7在甲状腺乳头状微小癌中的表达及临床意义 被引量:2

Expression and Clinical Significance of The Chemokine Receptor CCR7 in Thyroid Papillary Microcarcinoma
原文传递
导出
摘要 目的探讨CCR7在甲状腺乳头状微小癌中表达情况及其与甲状腺乳头状微小癌临床病理特征的关系。方法采用免疫组织化学S-P法检测31例甲状腺乳头状微小癌,34例直径>1 cm的甲状腺乳头状癌、34例结节性甲状腺肿以及12例甲状腺乳头状微小癌对侧正常甲状腺组织中CCR7的表达情况。结果 CCR7在甲状腺乳头状微小癌及直径>1 cm甲状腺乳头状癌中的表达阳性率均为100%,其差异无统计学意义(P>0.05),而在结节性甲状腺肿和正常甲状腺组织中CCR7的表达阳性率分别为64.7%和33.3%,与甲状腺乳头状微小癌相比差异有统计学意义(P<0.05)。CCR7的表达与患者性别、年龄、侵犯甲状腺被膜及淋巴结转移均无关(P>0.05)。结论 CCR7的表达在甲状腺乳头状微小癌和直径>1 cm甲状腺乳头状癌中均呈高表达,两者可能具有相同的生物学特性,两者均易发生颈淋巴结转移,均需要进行颈淋巴结(中央区)清扫。 Objective To explore the expression of chemokine receptor CCR7 in thyroid papillary microcarcinoma tissues and the relationship with clinicopathological features.Methods The CCR7 expressions in 31 cases of thyroid papillary microcarcinoma,34 cases of thyroid papillary carcinoma which diameter〉1 cm,34 cases of nodular goiter,and 12 cases of thyroid papillary microcarcinoma contralateral normal thyroid tissues were detected by using immunohistochemistry S-P method.Results The expression positive rates of CCR7 in thyroid papillary microcarcinoma and papillary thyroid carcinoma which diameter〉 1 cm were both 100%,the difference had not statistically significant (P〉0.05).In nodular goiter and normal thyroid tissues,the expression positive rate of CCR7 was 64.7% and 33.3%,respectively,and compared with thyroid papillary microcarcinoma,the difference had statistically significant(P〈0.05).There were not relations between the expression of CCR7 and patient’s gender,age,capsule invasion,and lymph node metastasis(P〉0.05).Conclusions The CCR7 in thyroid papillary microcarcinoma and thyroid papillary carcinoma which diameter〉 1 cm are both high expressions,and have the same bionomics,both prone to cervical lymph node metastasis,and the radical neck dissection(central area) are both need to take.
出处 《中国普外基础与临床杂志》 CAS 2012年第4期372-376,共5页 Chinese Journal of Bases and Clinics In General Surgery
基金 中国博士后科学基金第三批特别资助项目(项目编号:201003759)~~
关键词 趋化因子受体CCR7 甲状腺乳头状微小癌 甲状腺乳头状癌 淋巴结转移 Chemokine receptor CCR7; Thyroid papillary microcarcinoma; Thyroid papillary carcinoma; Lymph node metastasis
  • 相关文献

参考文献13

  • 1Caglih P, Zappulla E, Costa S, et al. Differentiated thyroid cancer: role of the lymph node dissection [J]. G Chir, 2010, 31 (6-7): 293-295.
  • 2Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone[J]. Laryngoscope, 2009, 119(6): 1135-1139.
  • 3贺青卿,庄大勇,郑鲁明,范子义,孙英刚,朱金明,李燕宁,李学亮,范西红.全甲状腺切除加功能性颈淋巴结清扫治疗甲状腺乳头状癌172例[J].中华普通外科杂志,2010,25(8):611-615. 被引量:20
  • 4Cassier PA, Treilleux I, Bachelot T, et al. Prognostic value of the expression of C-Chemokine receptor 6 and 7 and their ligands in non-metastatic breast cancer [J]. BMC Cancer, 2011, 11 : 213.
  • 5Schaeuble K, Hauser MA, Singer E, et al. Cross-talk between TCR and CCR7 signaling sets a temporal threshold for enhanced T lymphocyte migration [J]. J Immunol, 2011, 187(11): 5645- 5652.
  • 6贺青卿,崔玉宏,赵娟.甲状腺乳头状微小癌的治疗策略[J].中华内分泌外科杂志,2010,4(6):421-423. 被引量:9
  • 7Cunningham HD, Shannon LA, Calloway PA, et al. Expression of the C-C chemokine receptor 7 mediates metastasis of breast cancer to the lymph nodes in mice [J]. Transl Oncol, 2010, 3(6): 354-361.
  • 8贺青卿,庄大勇,魏金祥.甲状腺乳头状癌外科治疗策略[J].山东大学耳鼻喉眼学报,2011,25(5):7-10. 被引量:14
  • 9熊斌,王崇树.趋化因子受体CXCR4和CCR7在甲状腺癌中的表达及其临床病理意义[J].中国普外基础与临床杂志,2011,18(12):1301-1304. 被引量:8
  • 10Issa A, Le TX, Shoushtari AN, et al. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell- lymphatic cross-talk promote invasive phenotype [J]. Cancer Res, 2009, 69(1): 349-357.

二级参考文献84

  • 1马飞,宁力,张颖妹,徐兵河.趋化因子受体CCR7促进乳腺癌细胞的趋化与侵袭[J].第四军医大学学报,2004,25(20):1883-1886. 被引量:21
  • 2关海霞,单忠艳,米小轶,王恩华,滕卫平.普遍食盐碘化前后甲状腺癌发病变化的11年病理资料分析[J].中国医科大学学报,2006,35(3):284-285. 被引量:106
  • 3Zaydfudim V,Feurer ID,Griffin MR,et al.The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma.Surgery,2008,144:1070-1078.
  • 4Kim TY,Hong SJ,Kim JM,et al.Prognostic parameters for recurrence of papillary thyroid microcarcinoma.BMC Cancer,2008,14:296-307.
  • 5Davidson HC,Park BJ,Johnson JT.Papillary thyroid cancer:controversies in the management of neck metastasis.Laryngoscope,2008,118:2161-2165.
  • 6Pitt SC,Sippel RS,Chen H.Contralateral papillary thyroid cancer:does size matter? Am J Surg,2009,197:342-347.
  • 7Chagas JF,Aquino JL,Pascoal MB,et al.Multicentricity in the thyroid differentiated carcinoma.Braz J Otorhinolaryngol,2009,75:97-100.
  • 8Ito Y,Miyauchi A.Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.Endocr J,2009,56:177-192.
  • 9Cooper DS,Doherty GM,Haugen BR,et al.Management guidelines for patients with thyroid nodules and differentiated thyroid cancer.Thyroid,2006,16:109-142.
  • 10Choi SJ,Kim TY,Lee JC,et al.Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma? Clin Exp Otorhinolaryngol,2008,1:41-45.

共引文献44

同被引文献11

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部